Pharmacokinetics of Indinavir and Nelfinavir in Treatment-Naive, Human Immunodeficiency Virus-Infected Subjects

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 3, 2004, Pages 918-923

  DiCenzo, Robert ^a   Forrest, Alan ^a   Fischl, Margaret A ^b   Collier, Ann ^c   Feinberg, Judith ^d   Ribaudo, Heather ^e   DiFrancecso, Robin ^a   Morse, Gene D ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; INDINAVIR; NELFINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; BLOTTING, WESTERN; FEMALE; HALF-LIFE; HIV INFECTIONS; HUMANS; INDINAVIR; MALE; NELFINAVIR;

EID: 1442275659     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.3.918-923.2004     Document Type: Article

References (12)

1. Acosta, E. P., J. G. Gerber, and the Adult Pharmacology Committee of the AIDS Clinical Trials Group. 2002. Position paper on therapeutic drug monitoring of antiviral agents. AIDS Res. Hum. Retrovir. 18:825-834.
2. Baede-van Dijk, P. A., P. W. Hugen, C. P. Verweij-van Wissen, P. P. Koopmans, D. M. Burger, and Y. A. Hekster. 2001. Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. AIDS 15:1057-1058.
3. Capparelli, E. V., J. L. Sullivan, L. Mofenson, E. Smith, B. Graham, P. Britto, M. I. Becker, D. Holland, J. D. Connor, K. Luzuriaga, et al. 2001. Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants. Pediatr. Infect. Dis. J. 20:746-751.
4. Casado, J. L., S. Moreno, K. Hertogs, F. Dronda, A. Antela, P. Dehertogh, M. J. Perez-Elias, and A. Moreno. 2002. NELSANE study. Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen. AIDS 16:47-52.
5. Fellay J., C. Marzolini, E. R. Meaden, D. J. Back, T. Buclin, J. P. Chave, L. A. Decosterd, H. Furrer, M. Opravil, G. Pantaleo, D. Retelska, L. Ruiz, A. H. Schinkel, P. Vernazza, C. B. Eap, A. Telenti, et al. 2002. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics; study. Lancet 359:30-36.
6. Fischl, M. A., H. J. Ribaudo, A. C. Collier, A. Erice, M. Giuliano, M. Dehlinger, J. J. Eron, Jr., M. S. Saag, S. M. Hammer, S. Vella, G. D. Morse, J. E. Feinberg, L. M. Denter, S. H. Eshleman, and the Adult AIDS Clinical Trials Group 388 Study Team. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J. Infect. Dis. 188:625-634. (Erratum, 188:1083.)
7. Fletcher, C. V., P. L. Anderson, T. N. Kakuda, T. W. Schacker, K. Henry, C. R. Gross, and R. C. Brundage. 2002. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 16:551-560.
8. Haas, D. W., E. Arathoon, M. A. Thompson, R. D. Pedro, J. E. Gallant, D. E. Uip, J. Currier, L. M. Noriega, D. S. Lewi, P. Uribe, L. Benetucci, P. Cahn, D. Paar, A. C. White, Jr., A. C. Collier, C. H. Ramirez-Ronda, C. Harvey, M. O. Chung, D. Mehrotra, J. Chodakewitz, B. Y. Nguyen, et al. 2000. Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine. AIDS 14:1973-1978.
9. Hsyu, P. H., M. D. Schultz-Smith, J. H. Lillibridge, R. H. Lewis, and B. M. Kerr. 2001. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob. Agents Chemother. 45:3445-3450.
10. Marzolini, C., T. Buclin, L. A. Decosterd, J. Biollaz, and A. Telenti. 2001. Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability. Ther. Drug Monit. 23:394-398.
11. Merry, C. 2001. Editorial comment on analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. AIDS 15:991-998.
12. Riddler, S. A., D. Havlir, K. E. Squires, B. Kerr, R. H. Lewis, K. Yeh, L. H. Wynne, L. Zhong, Y. H. Peng, P. Deutsch, and A. Saah. 2002. Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity. Antimicrob. Agents Chemother. 46:3877-3882.